Resveratrol and Cardiovascular Diseases.
Resveratrol and Cardiovascular Diseases.
复制标题
DOI：
10.3390/nu8050250
复制
发表时间：
2016-05-02
期刊：
影响因子：
5.9
通讯作者：
Bonnefont-Rousselot D
中科院分区：
文献类型：
--
作者：
Bonnefont-Rousselot D
心血管疾病（CVD）发病率的增加刺激了对可以改善心血管健康的物质的研究。其中，白藜芦醇（RES），一种多酚类化合物，特别是存在于葡萄和红葡萄酒，已被卷入“法国悖论”。RES以其抗氧化和抗炎特性以及其上调内皮NO合酶（eNOS）的能力而闻名。RES能清除·OH/O2·−和过氧化氢自由基，抑制脂质过氧化过程。此外，在牛主动脉内皮细胞（BAEC）在葡萄糖诱导的氧化应激下，RES恢复二甲基精氨酸二甲氨基水解酶（DDAH）的活性，DDAH是一种降解eNOS内源性抑制剂的酶，称为不对称二甲基精氨酸（ADMA）。因此，RES可以改善·NO的利用率，并减轻糖尿病中观察到的内皮功能障碍。临床前研究已经可以确定分子靶点（SIRT-1、AMPK、Nrf 2、NFκB.）;然而，人体临床试验有限，并且在研究中使用高剂量RES补充剂导致结果解释困难，而红葡萄酒中存在低RES浓度。关于RES在CVD（动脉粥样硬化、高血压、卒中、心肌梗死、心力衰竭）中的潜在有益作用的讨论应将临床前研究结果与临床试验结果进行比较。
The increased incidence of cardiovascular diseases (CVDs) has stimulated research for substances that could improve cardiovascular health. Among them, resveratrol (RES), a polyphenolic compound notably present in grapes and red wine, has been involved in the “French paradox”. RES is known for its antioxidant and anti-inflammatory properties and for its ability to upregulate endothelial NO synthase (eNOS). RES was able to scavenge •OH/O2•− and peroxyl radicals, which can limit the lipid peroxidation processes. Moreover, in bovine aortic endothelial cells (BAEC) under glucose-induced oxidative stress, RES restored the activity of dimethylargininedimethylaminohydrolase (DDAH), an enzyme that degrades an endogenous inhibitor of eNOS named asymmetric dimethylarginine (ADMA). Thus, RES could improve •NO availability and decrease the endothelial dysfunction observed in diabetes. Preclinical studies have made it possible to identify molecular targets (SIRT-1, AMPK, Nrf2, NFκB…); however, there are limited human clinical trials, and difficulties in the interpretation of results arise from the use of high-dose RES supplements in research studies, whereas low RES concentrations are present in red wine. The discussions on potential beneficial effects of RES in CVDs (atherosclerosis, hypertension, stroke, myocardial infarction, heart failure) should compare the results of preclinical studies with those of clinical trials.